GlassScriptPhysician profile
David A Stephens
NPI 1851805055
$9,355.98
in general payments reported to CMS, 2019-2025
39 companies · $1,877 in 2025
The $1,877 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,548 · 2022: $2,196 · 2023: $1,819 · 2024: $1,916 · 2025: $1,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,611.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,716.47 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,412.92 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,037.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $744.23 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $663.54 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corium, LLC | $445.95 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $371.57 | 2024-2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $281.77 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.03 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $221.65 | 2024 | Veozah |
| Genentech USA, INC. | $209.24 | 2021-2022 | |
| Pfizer INC. | $199.14 | 2023-2025 | |
| Amgen INC. | $196.91 | 2021-2024 | Evenity, Prolia, Repatha |
| Idorsia Pharmaceuticals US INC | $176.88 | 2022-2024 | Quviviq |
| Abbvie INC. | $176.51 | 2021-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.